Real-World Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A 16-Week Single-Center Retrospective Cohort Study Compared with Upadacitinib and Baricitinib
Abrocitinib demonstrates real-world efficacy and safety in moderate-to-severe AD, including patients with inadequate responses to other dupilumab or JAK inhibitors, including those with prior exposure to biologics or other JAK inhibitors.
Authors
- So Yun Park (ORCID: https://orcid.org/0000-0003-4747-0248)
- Hye Jung Jung (ORCID: https://orcid.org/0000-0003-0995-5711)
- M R Park
- Yu Sung Choi (ORCID: https://orcid.org/0000-0001-8308-4091)
- Ho Eun Gwag
- Seok Jae Heo
- Mi Youn Park (ORCID: https://orcid.org/0000-0002-1824-8309)
- Narang Hong
- Jiyoung Ahn
Institutions
- Yonsei University (KR)
- Soonchunhyang University (KR)
- Soonchunhyang University Hospital Seoul (KR)
- National Medical Center (KR)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1007/s13555-026-01679-0
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00